birders---> maybe a good winter coming for northern finches and friends finchnetwork.org/winter-finch... #birders #birding #massbird

lovely writeup at BBC #Seurat bbc.com/culture/arti...

A very interesting bispecific ADC highlighted today by @JacobPlieth on X - oncologypipeline.com/apexonco/bri... while this discussion is focused on lung cancer, the first approval for iza-bren likely in nasopharyngeal carcinoma $BMY #SystImmune

odd dynamic between clean energy needs and protecting ocean/avian ecosystems hard to choose a side? yep... chng.it/ThgpyJY2Pw

Mars, duh.

for #biotech and advanced therapeutics followers, a cool paper here: doi.org/10.1016/j.me...

Esobiotec's in vivo CAR-T data out in Lancet, n=4, multiple myeloma. These are the data that drove the $AZN acquisition, showing that the in vivo CAR-T results were equal to the ex vivo CAR-T results from Pregene w the same BCMA-CAR www.thelancet.com/journals/lan...

Concentra goes shopping again, adds CARGO to its market basket finance.yahoo.com/news/cargo-t... Cargo, IGM, Elevation Oncology, Kronos Bio, Allakos

HER3 activation and overexpression in cancers makes this antigen an attractive target for antibody therapeutics ---> a rapidly expanding drug development landscape has emerged sugarconebiotech.com/insights

In the inflammatory #fibrosis space, $PLRX stopped development of bexotegrast avb6/avb1 inhibitor for the treatment of IPF "due to worsening of IPF and acute IPF exacerbation, respiratory-related hospitalization, and/or all-cause mortality" (27 June 2025). Yikes.

tgif. goosebumps at this Wharf Rat, starts @ 10:28 www.youtube.com/watch?v=I1FV... the wheel is nice too, but man... 'i got up and wandered'

quick series on emerging #cancer targets w updates post #ASCO25 from the biopharma/venture capital consultancy experts - sugarconebiotech.com #biotech #bioblue www.sugarconebiotech.com/insights/goo...

June snacks

Remarkable - Swallow-Tailed Kites are using a highly localized cicada emergence as an excuse to hang around and possibly nest in Mashpee MA, way north of their closest haunts in N.Carolina and FL #birding #birdblue

A quick note of thanks to Esobiotec's management and Board of Directors as the AstraZeneca acquisition is now completed. Our job is done with this happy exit, and so the current Board, myself included, disperses. Its a bittersweet moment for me. #biotech #biosky www.astrazeneca.com/media-centre...

ln early March I talked about the bispecific antibody landscape in IAI, specifically for atopic dermatitis and asthma. This remains a red hot area #biosky #biotech ... and we've added analysts to keep up the pace. See sugarconebiotech.com/insights/nov...

#biotech #biosky

Here we look at the state of In Vivo CAR T cell technology and companies, post Astra Zeneca's billion dollar Esobiotec acquisition and amid biotech's financing woes: www.sugarconebiotech.com/insights

Here we look at the state of In Vivo CAR T cell technology and companies, post Astra Zeneca's billion dollar Esobiotec acquisition and amid biotech's financing woes: www.sugarconebiotech.com/insights

Bye-Bei TIGIT - a lesson in the dangers of mediocre science butting up against the challenges of complex ligand/receptor interactions, FcReceptor biology, and cancer resistance mechanisms Beigene news via #ApexOnco www.oncologypipeline.com/apexonco/bei...

haven't listened to this '77 very much, it's blistering www.youtube.com/watch?v=wPgE...

omg it worked! #bispecifics #oncology #Tcells www.sugarconebiotech.com/insights/ale... cc www.aletabio.com

T CELL ENGAGER PROTEINS WITH BUILT IN COSTIMULATORY DOMAINS THAT TURN TUMOR CELLS INTO IMMUNE CELL MIMICS AND TRIGGER IMMUNE SYNAPSE SIGNALING ... www.aletabio.com/blog-1-1/ale... @BioAleta

Our most potent T cell bispecifics leverage natural T cell immunology to kill cancer cells ... www.sugarconebiotech.com/insights/ale... proprietary technology that works just as well with CAR T engager proteins #aletabio #bispecifics #CARTcells

Whoa #biotech $CRGX implodes.

news for #bioblue #biotech www.theguardian.com/business/202...

from last year, a blockbuster- The EBMT Handbook. Hematopoietic Cell Transplantation and Cellular Therapies" bit.ly/41n3IKb

and we provide some broader #biotech #bioblue context www.sugarconebiotech.com/insights/pd1...

the ivonescimab clinical data have published in @thelancet.bsky.social www.thelancet.com/journals/lan... and they added some great commentary

maybe $LEGN can test the thesis that there is only bad news for #biotech stocks ... they think 10,000 patients will receive CARVYKTI in 2025 ... looking at $2B in sales for this year

interesting Phase 3 results for rocatinlimab, an anti-OX40 antagonist antibody for atopic dermatitis. This therapeutic hit on all endpoints... $AMGN an anti-OX40L antibody also coming from $SNY www.amgen.com/newsroom/pre...

how to survive reviewing those papers you promised to review. #protip for #biotech and #academics archive.org/details/ttb2...

I use youtube for short videos on cooking, walkabouts with the dog, and primers on biotech and drug development here's "cooking while the dog sleeps" resulting in a very nice dish #dashi #bokchoi #rumcure #bacon youtu.be/7356YW9CNIs

hey #biotech this week was the annual meeting of AAAAI so we are talking asthma and atopic dermatitis In honor of AAAAI week we're talking about asthma and atopic dermatitis - the future is bispecific! www.sugarconebiotech.com/insights/nov...

A bit more #bioblue #biotech #oncology news from aletabiotherapeutics.com - we've invented a remarkable way to boost the functionality of T Cell Engager proteins (TCE) by making tumor cells look more like an immune cell. The "engaged" T cells just LOVE the embrace. www.nature.com/articles/d43...

hey #bioblue --- in a time of simply ridiculous copycat drug development we found a few examples of real innovation. Part 1 - novel bispecific therapeutics in oncology. Posted only at sugarconebiotech.com. www.sugarconebiotech.com/insights/nov...

Arcane. Amazing.

Lovely book.

Paul D. Rennert @PDRennert · coming soon to the sugarconebiotech.com blog - interesting bispecific programs found in company pipelines eg. $CMPX $BCAX and more and coming soon to the aletabio.com blog - a very novel class of engager molecules

Trump just added the CFIUS nail to the $XBI coffin. #biotech #China #bioblue

Very nice in vivo CAR T news from Esobiotec in the EU: www.morningstar.com/news/globe-n... disclosure: BOD member

When you're dictating because of chronic wrist tendinitis due to chronic PowerPoint production but the dog is staring at you: "Do you wanna go out or you hungry which is it you gotta tell me I can’t read your flipping mind" is probably inappropriate in the middle of an invention disclosure

clever idea, once pursued by Xios, we worried about potential autoimmune toxicities however

A blistering Mountain Jam, courtesy of The Tedeshi Trucks Band and @archive.org cc @gilman.bsky.social @bourkepr.bsky.social archive.org/details/ttb2...

We think that the copycat stampede in PD-1 x VEGF pathway bispecifics betrays weakness in innovation and ignores looming competition. cc sugarconebiotech.com

CARGO runs aground investors.cargo-tx.com/news-release... #bioblue #bluebio #biotech

Another bell tolls for TILs. #biosky #biotech ir.turnstonebio.com/news-release...

VEGF/PD-1 pathway bispecifics: Hype versus Hope www.sugarconebiotech.com/insights/pd1...

VEGF/PD-1 pathway bispecifics: Hype versus Hope www.sugarconebiotech.com/insights/pd1...

Another bell tolls for TILs. #biosky #biotech ir.turnstonebio.com/news-release...